Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06512935

Ventilator Pressure and Optimization of Compliance and Hemodynamics

In preterm infants < 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory pressure (PEEP) of best compliance will increase the cardiac output and improve oxygenation. This study may emphasize using point-of-care echocardiography along with electrical impedance tomography (EIT) to optimize ventilator settings in preterm infants.

Infants will be randomized to a 4-hour crossover period of increasing and decreasing PEEP in random order from baseline to determine compliance, oxygenation, and cardiac hemodynamics at each step using echocardiography (ECHO) and EIT measurements. There will be a 15-minute washout period after changes prior to data collection.

Recruiting

Interested in participating?

Request Info

Key information

About this study

In preterm infants < 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory pressure (PEEP) of best compliance will increase the cardiac output and improve oxygenation. This study may emphasize using point-of-care echocardiography along with EIT to optimize ventilator settings in preterm infants.

Neonatal ventilation is a critical intervention to support breathing for newborns with respiratory distress syndrome (RDS), underdeveloped lungs, and evolving bronchopulmonary dysplasia (BPD). Positive airway pressure helps maintain patency of the airways and improves ventilation and oxygenation by maintaining the functional residual capacity (FRC) and keeping the alveoli patent. Peak inspiratory pressure (PIP) and positive end-expiratory pressure (PEEP) are terms commonly used in mechanical ventilation to describe the pressures applied to the respiratory system during the different phases of the breathing cycle. These parameters are essential in managing and optimizing ventilation for infants with respiratory failure.

This study will include preterm infants with recovering RDS born at age < 34 weeks of gestational age on respiratory support via conventional mechanical ventilation or on high-frequency jet ventilation (HFJV). Infants will be randomized to the order of testing, increasing the PEEP (+1 cmH2O and +2 cmH2O) or decreasing the PEEP (+1 cmH2O and +2 cmH2O) with baseline measurements and Echo done at original PEEP and each subsequent PEEP.

Following informed consent, randomization will be performed using sequentially numbered sealed opaque envelopes. The randomization envelope will be signed before it is opened just before starting the study on each infant to indicate the first intervention for the infant.

This will be a single-center, randomized crossover study. The randomization envelope will be signed before it is opened just before starting the study on each infant to indicate the first intervention for the infant.

Randomization will occur after a baseline assessment of cardiac hemodynamics and respiratory status at the current set PEEP level. Infants will be randomized to the order of changes in PEEP levels during mechanical ventilation - increase followed by decrease versus decrease followed by increase. Randomization will use opaque sealed envelopes of varying block sizes from 2-4 with a 1:1:1:1 allocation ratio.

Infants will be randomized to a 4-hour crossover period of increasing and decreasing PEEP in random order from baseline and there will be a 15-minute washout period after changes before data collection.

All infants enrolled in the study will have routine monitoring, uniform target saturation ranges of 91-95% with alarm limits set at 88-95%, and standard care for the duration of the study. Pulse oximetry recordings will be downloaded using ixTrend (iexcellence, Wildau, Germany) software to a secure computer system for later data analysis.

Infants will continue standard treatment as recommended by the treating physician and will act as their own controls.

Primary secondary outcomes are described below. Electrical impedance tomography data will be collected in the Syntec machine and safely secured in the university computer system. Pulse oximetry recordings will be downloaded using ixTrend software to a secure computer system for later data analysis.

ECHO results will be stored in the unit ECHO machine and results will be reported by certified cardiologists blinded to the data collected to improve the study design's internal and external validity.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Preterm infants with recovering respiratory distress syndrome (RDS) who were born at a gestational age < 34 weeks and are receiving respiratory support via conventional mechanical ventilation or on HFJV.

  • Post-natal age > 7 days and less than 1 month (outside golden week protocol)
  • Gestational age ≥ 21 weeks and ≤ 34 week
  • Infants with written informed consent obtained from legal guardian

Exclusion criteria

  • Blood culture-positive sepsis
  • Congenital anomalies affecting respiration
  • Cyanotic or ductal-dependent congenital heart disease
  • Newborns who are considered too unstable for study enrolment per neonatology attending
  • Newborns on pressors or steroids for maintaining cardiac output
  • Non-invasive ventilation or newborn with significant BPD (bronchopulmonary dysplasia) with pulmonary hypertension (HTN)
  • Open skin wounds or abrasions on the chest wall.

Treatment and study plan

Increase in the PEEP followed by decrease in the PEEP

Other

Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics

Decrease in the PEEP followed by increase in the PEEP

Other

Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics

Primary outcomes

  1. Change in cardiac index with increase/decrease in PEEP as measured by ECHO and EIT

    Time frame: During a 4 hour cross-over period on either intervention

  2. PEEP of best compliance and best oxygenation as per EIT measurements

    Time frame: During a 4 hour cross-over period on either intervention

Secondary outcomes

  1. Tidal volume variation

    Time frame: During a 4 hour cross-over period on either intervention

  2. Oxygen saturation index

    Time frame: During a 4 hour cross-over period on either intervention

  3. End-expiratory lung impedance (EELI), End-inspiratory lung impedance (EILI)

    Time frame: During a 4 hour cross-over period on either intervention

  4. Transcutaneous carbon dioxide (TcCO2) values in response to varying PEEP levels

    Time frame: During a 4 hour cross-over period on either intervention

  5. Respiratory Severity Score (RSS)

    Time frame: During a 4 hour cross-over period on either intervention

    RSS: mean airway pressure (MAP) x fraction of inspired oxygen (FiO2)

  6. oxygen saturation (SpO2) values

    Time frame: During a 4 hour cross-over period on either intervention

  7. % tidal distribution

    Time frame: During a 4 hour cross-over period on either intervention

Study contacts

Contact information is provided by the study sponsor or research team.

Colm P Travers, MD

CONTACT

[email protected]

Kulsajan S Bhatia, MD

CONTACT

[email protected]

9172149882

Sponsors and collaborators

Lead sponsor

University of Alabama at Birmingham

Other

Registry information

Official study title

Ventilator Pressure and Optimization of Compliance and Hemodynamics: VPOCH Trial

Acronym: VPOCH

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 22, 2024
Registry last updated
May 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.